TCM
IMVT icon

TCG Crossover Management’s Immunovant IMVT Stock Holding History

TCG Crossover Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$172M Hold
4,457,988
– – 4.13% 5
2026
Q1 		$111M Buy
4,457,988
+2,797,055
+168% +$72.4M 3.17% 8
2025
Q4 		$42.2M Buy
+1,660,933
New +$37M 1.4% 20
2023
Q4 		– Sell
-334,853
Closed -$12.9M – 30
2023
Q3 		$12.9M Sell
334,853
-320,000
-49% -$7.23M 1.89% 21
2023
Q2 		$12.4M Hold
654,853
– – 2.04% 14
2023
Q1 		$10.2M Sell
654,853
-200,000
-23% -$3.47M 1.98% 15
2022
Q4 		$15.2M Buy
+854,853
New +$10.8M 2.68% 14

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCG Crossover Management's IMVT Position: Q2 2026 in Review

TCG Crossover Management held its Immunovant (IMVT) position steady in Q2 2026 at 4,457,988 shares worth $172M. The position accounts for 4.13% of the portfolio, ranked #5.

TCG Crossover Management first reported a position in IMVT in Q4 2022 and has held it in 7 quarters since. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • TCG Crossover Management held 4,457,988 shares of Immunovant worth $172M as of Q2 2026.
  • TCG Crossover Management left its Immunovant share count unchanged in Q2 2026.
  • Immunovant made up 4.13% of TCG Crossover Management's portfolio in Q2 2026, its #5 holding.
  • TCG Crossover Management first reported a position in Immunovant in Q4 2022 and has held it in 7 quarters since.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on TCG Crossover Management's 13F filing for Q2 2026, filed 14 Aug 2026.